COMMUNIQUÉS West-GlobeNewswire

Savara to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 7, 2018
01/11/2018
AUSTIN, Texas, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its third quarter 2018 financial results on Wednesday, November 7, 2018. [...]
3rd Quarter Results
01/11/2018
Shire Delivers Product Sales Growth of 6% and Continues to Execute Against Key Priorities in Q3 2018 Delivered product sales of $3.8 billion; growth driven by Immunology, recently-launched products, and international [...]
Progenics Pharmaceuticals Sets Third Quarter 2018 Financial Results and Business Update Call for November 8
01/11/2018
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced [...]
Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress
01/11/2018
– Rilonacept pivotal Phase 3 clinical trial initiating this year – Mavrilimumab pre-IND meeting complete; plans for global Phase 2 clinical trial advancing – KPL-716 advancing into multiple chronic pruritic diseases, [...]
Genocea Reports Third Quarter 2018 Financial and Operating Results
01/11/2018
Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial enrolling patients Presenting novel findings at upcoming SITC conference Conference call today at 9:00 am ET CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE [...]
Evelo Biosciences Reports Third Quarter 2018 Financial Results and Recent Business Highlights
01/11/2018
-- Approval to Initiate Phase 1b Trial of EDP1815 in Psoriasis and Atopic Dermatitis: Dosing of First Patient Expected in 4Q18 -- -- Initiation of Investigator-Sponsored Phase 2a Trial of EDP1503 in Metastatic Melanoma [...]
Spring Bank Announces Three Poster Presentations on Its Next-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
01/11/2018
HOPKINTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, [...]
Chimerix to Announce Third Quarter 2018 Financial Results on November 8, 2018
01/11/2018
DURHAM, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live [...]
Establishment Labs to Release Third Quarter 2018 Financial Results on November 13, 2018
01/11/2018
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA) today announced that the Company will release its third quarter 2018 financial results on Tuesday, November 13, 2018, prior to [...]
Zafgen to Host Conference Call to Discuss Third Quarter 2018 Financial Results
01/11/2018
BOSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]
Operational Update
01/11/2018
Highlights Site selection process advancing for planned TACTI-002 Phase II trial which will include recruitment of up to 110 patients AIPAC Phase IIb recruitment reaches 155 patients or more than 68% of total patients [...]
Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7th
01/11/2018
SANTA MONICA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, [...]
Selecta Biosciences to Report Third Quarter 2018 Financial Results and Update on SEL-212 Development Strategy, including Planned Head-to-Head Study versus Krystexxa
01/11/2018
WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating [...]
Sun BioPharma, Inc. to Present Results of New Pancreatitis Study at American Pancreatic Association Meeting in Miami Beach, FL
01/11/2018
MINNEAPOLIS, Minn., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company specializing in disruptive therapeutics for pancreatic diseases, announced today that [...]
Aeterna Zentaris Announces Novo Nordisk to acquire rights to Macrilen™ in United States and Canada
01/11/2018
CHARLESTON, S.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) announces that it was advised yesterday that Strongbridge BioPharma Plc has signed an agreement with Novo Nordisk A/S [...]
TRHC Praises Signing of SUPPORT for Patients and Communities Act
01/11/2018
MOORESTOWN, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc . (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, applauds the signing into law of the [...]
Catalyst Biosciences Reports Third Quarter Operating & Financial Results and Provides a Corporate Update
01/11/2018
Presented Updated Positive Interim Data from the Phase 2/3 Study of Marzeptacog Alfa (Activated) (FVIIa) at Two Scientific Meetings Published Data from Phase 1 Study of Marzeptacog Alfa (Activated) in the Journal of [...]
MannKind Corporation Reports 2018 Third Quarter Financial Results
01/11/2018
Conference Call to Begin Today at 9:00 AM ET Executed license and collaboration agreement with United Therapeutics for up to $95 million in upfront and milestone payments plus royalties Executed research agreement for a [...]
Radius Health Announces Third Quarter 2018 Operating Results and Financial Guidance for FY 2018 and FY 2019
01/11/2018
TYMLOS® U.S. net sales continued to increase in the third quarter of 2018, totaling $27.6 million. 2019 Medicare Part D coverage for TYMLOS increased from 44% to 64% Elacestrant Phase 3 study to target a broader patient [...]

Pages